Seth Cohen
@sethalosporin.bsky.social
ID doc, Director of Infection Prevention at UWMC (Seattle), Medical Education, Epidemiology. Lover of audiobooks, birds, and bagels.
Pinned
Seth Cohen
@sethalosporin.bsky.social
Β· Dec 17
π¨π£π¨π£
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
Love it, thanks Joseph!
December 23, 2025 at 3:44 AM
Love it, thanks Joseph!
Interested in thoughts on any of these trials as well as suggestions for other literature to include. @uwidfellowship.bsky.social @pergamic.bsky.social @rupalij.bsky.social
December 22, 2025 at 3:22 PM
Interested in thoughts on any of these trials as well as suggestions for other literature to include. @uwidfellowship.bsky.social @pergamic.bsky.social @rupalij.bsky.social
Want the full reading list?
See βEssential Publications in Infectious Diseases 2025β link below, with more details on essential literature from this year:
pdf: app.box.com/s/ny7m9d0pdi...
Ppt on request
Thanks for reading and for everything you do.
See βEssential Publications in Infectious Diseases 2025β link below, with more details on essential literature from this year:
pdf: app.box.com/s/ny7m9d0pdi...
Ppt on request
Thanks for reading and for everything you do.
Important ID publications 2025 Cohen.pdf | Powered by Box
app.box.com
December 22, 2025 at 3:22 PM
Want the full reading list?
See βEssential Publications in Infectious Diseases 2025β link below, with more details on essential literature from this year:
pdf: app.box.com/s/ny7m9d0pdi...
Ppt on request
Thanks for reading and for everything you do.
See βEssential Publications in Infectious Diseases 2025β link below, with more details on essential literature from this year:
pdf: app.box.com/s/ny7m9d0pdi...
Ppt on request
Thanks for reading and for everything you do.
8οΈβ£ Big Picture Takeaways
π Guidelines often rest on limited evidence
π Treatment durations keep shrinkingβeven for TB
π PO often >> IV. Safe and patient centered.
π RSV prevention is a true breakthrough
π Despite setbacks, this is still an exciting time to be in ID π
π Guidelines often rest on limited evidence
π Treatment durations keep shrinkingβeven for TB
π PO often >> IV. Safe and patient centered.
π RSV prevention is a true breakthrough
π Despite setbacks, this is still an exciting time to be in ID π
December 22, 2025 at 3:22 PM
8οΈβ£ Big Picture Takeaways
π Guidelines often rest on limited evidence
π Treatment durations keep shrinkingβeven for TB
π PO often >> IV. Safe and patient centered.
π RSV prevention is a true breakthrough
π Despite setbacks, this is still an exciting time to be in ID π
π Guidelines often rest on limited evidence
π Treatment durations keep shrinkingβeven for TB
π PO often >> IV. Safe and patient centered.
π RSV prevention is a true breakthrough
π Despite setbacks, this is still an exciting time to be in ID π
7οΈβ£ Vaccines: A Standout Year
RSV vaccines: ~80β90% reduction in RSV hospitalizations in adults β₯60
mRNA flu vaccines: superior efficacy vs standard flu shots, with more reactogenicity
Emerging data suggest mRNA vaccines may synergize with cancer immunotherapy
Woot woot! π
RSV vaccines: ~80β90% reduction in RSV hospitalizations in adults β₯60
mRNA flu vaccines: superior efficacy vs standard flu shots, with more reactogenicity
Emerging data suggest mRNA vaccines may synergize with cancer immunotherapy
Woot woot! π
December 22, 2025 at 3:22 PM
7οΈβ£ Vaccines: A Standout Year
RSV vaccines: ~80β90% reduction in RSV hospitalizations in adults β₯60
mRNA flu vaccines: superior efficacy vs standard flu shots, with more reactogenicity
Emerging data suggest mRNA vaccines may synergize with cancer immunotherapy
Woot woot! π
RSV vaccines: ~80β90% reduction in RSV hospitalizations in adults β₯60
mRNA flu vaccines: superior efficacy vs standard flu shots, with more reactogenicity
Emerging data suggest mRNA vaccines may synergize with cancer immunotherapy
Woot woot! π
6οΈβ£ COVID Therapeutics: Reappraisal
Large real-world data suggest Paxlovid offers little benefit in highly vaccinated older adults.
Its role in 2025 is increasingly narrow and should be framed honestly. π
Large real-world data suggest Paxlovid offers little benefit in highly vaccinated older adults.
Its role in 2025 is increasingly narrow and should be framed honestly. π
December 22, 2025 at 3:22 PM
6οΈβ£ COVID Therapeutics: Reappraisal
Large real-world data suggest Paxlovid offers little benefit in highly vaccinated older adults.
Its role in 2025 is increasingly narrow and should be framed honestly. π
Large real-world data suggest Paxlovid offers little benefit in highly vaccinated older adults.
Its role in 2025 is increasingly narrow and should be framed honestly. π
5οΈβ£ Antimicrobials: Find the niche
Cefiderocol: noninferior, not superior; reserve for salvage
Olorofim: bright spot in mold infections. Rare mold trials are hard!
Dalbavancin: viable consolidation therapy after S. aureus bacteremia clearance
Gepotidacin is here! π
Cefiderocol: noninferior, not superior; reserve for salvage
Olorofim: bright spot in mold infections. Rare mold trials are hard!
Dalbavancin: viable consolidation therapy after S. aureus bacteremia clearance
Gepotidacin is here! π
December 22, 2025 at 3:22 PM
5οΈβ£ Antimicrobials: Find the niche
Cefiderocol: noninferior, not superior; reserve for salvage
Olorofim: bright spot in mold infections. Rare mold trials are hard!
Dalbavancin: viable consolidation therapy after S. aureus bacteremia clearance
Gepotidacin is here! π
Cefiderocol: noninferior, not superior; reserve for salvage
Olorofim: bright spot in mold infections. Rare mold trials are hard!
Dalbavancin: viable consolidation therapy after S. aureus bacteremia clearance
Gepotidacin is here! π
4οΈβ£ Mpox: A Hard Lesson in Evidence
Randomized trials now show no clinical benefit of tecovirimat for mpox.
Animal models and uncontrolled observational data may have misled usβan important cautionary tale for outbreak therapeutics. π
Randomized trials now show no clinical benefit of tecovirimat for mpox.
Animal models and uncontrolled observational data may have misled usβan important cautionary tale for outbreak therapeutics. π
December 22, 2025 at 3:22 PM
4οΈβ£ Mpox: A Hard Lesson in Evidence
Randomized trials now show no clinical benefit of tecovirimat for mpox.
Animal models and uncontrolled observational data may have misled usβan important cautionary tale for outbreak therapeutics. π
Randomized trials now show no clinical benefit of tecovirimat for mpox.
Animal models and uncontrolled observational data may have misled usβan important cautionary tale for outbreak therapeutics. π
3οΈβ£ STIs: Paradigm Shifts
Two practice-changing NEJM trials:
Male partner treatment for bacterial vaginosis cut recurrence nearly in half
Twice-yearly lenacapavir for HIV PrEP showed ~90% protection
Implementation, cost, and access will determine real-world impact. π
Two practice-changing NEJM trials:
Male partner treatment for bacterial vaginosis cut recurrence nearly in half
Twice-yearly lenacapavir for HIV PrEP showed ~90% protection
Implementation, cost, and access will determine real-world impact. π
December 22, 2025 at 3:22 PM
3οΈβ£ STIs: Paradigm Shifts
Two practice-changing NEJM trials:
Male partner treatment for bacterial vaginosis cut recurrence nearly in half
Twice-yearly lenacapavir for HIV PrEP showed ~90% protection
Implementation, cost, and access will determine real-world impact. π
Two practice-changing NEJM trials:
Male partner treatment for bacterial vaginosis cut recurrence nearly in half
Twice-yearly lenacapavir for HIV PrEP showed ~90% protection
Implementation, cost, and access will determine real-world impact. π
2οΈβ£ Vector Control: Entomology β Outcomes
Three trials, three lessons:
Ivermectin MDA β malaria incidence
Permethrin baby wraps β infant malaria by 66%
Indoor residual spraying dramatically β mosquitoes but not infections
Bottom line: endpoints are key π
Three trials, three lessons:
Ivermectin MDA β malaria incidence
Permethrin baby wraps β infant malaria by 66%
Indoor residual spraying dramatically β mosquitoes but not infections
Bottom line: endpoints are key π
December 22, 2025 at 3:22 PM
2οΈβ£ Vector Control: Entomology β Outcomes
Three trials, three lessons:
Ivermectin MDA β malaria incidence
Permethrin baby wraps β infant malaria by 66%
Indoor residual spraying dramatically β mosquitoes but not infections
Bottom line: endpoints are key π
Three trials, three lessons:
Ivermectin MDA β malaria incidence
Permethrin baby wraps β infant malaria by 66%
Indoor residual spraying dramatically β mosquitoes but not infections
Bottom line: endpoints are key π
1οΈβ£ Guidelines: Shorter, Oral, Individualized
2025 continues the trend toward less is more:
CAP: shorter courses (3β5 days) if stable
TB: 4-month regimens now endorsed for select patients
cUTI: oral step-down even with bacteremia is appropriate
Individualize guidance!π
2025 continues the trend toward less is more:
CAP: shorter courses (3β5 days) if stable
TB: 4-month regimens now endorsed for select patients
cUTI: oral step-down even with bacteremia is appropriate
Individualize guidance!π
December 22, 2025 at 3:22 PM
1οΈβ£ Guidelines: Shorter, Oral, Individualized
2025 continues the trend toward less is more:
CAP: shorter courses (3β5 days) if stable
TB: 4-month regimens now endorsed for select patients
cUTI: oral step-down even with bacteremia is appropriate
Individualize guidance!π
2025 continues the trend toward less is more:
CAP: shorter courses (3β5 days) if stable
TB: 4-month regimens now endorsed for select patients
cUTI: oral step-down even with bacteremia is appropriate
Individualize guidance!π
𧡠Essential ID Papers for 2025: A Clinicianβs Guide
Each year brings a flood of amazing ID literature.
Here are candidates for some of the most important ID papers of 2025, spanning guidelines, trials, antimicrobials, and vaccines.
π
Each year brings a flood of amazing ID literature.
Here are candidates for some of the most important ID papers of 2025, spanning guidelines, trials, antimicrobials, and vaccines.
π
December 22, 2025 at 3:22 PM
𧡠Essential ID Papers for 2025: A Clinicianβs Guide
Each year brings a flood of amazing ID literature.
Here are candidates for some of the most important ID papers of 2025, spanning guidelines, trials, antimicrobials, and vaccines.
π
Each year brings a flood of amazing ID literature.
Here are candidates for some of the most important ID papers of 2025, spanning guidelines, trials, antimicrobials, and vaccines.
π
Love thisβ adding it to my teaching folder. Thanks for sharing Lisa!
October 24, 2025 at 4:26 AM
Love thisβ adding it to my teaching folder. Thanks for sharing Lisa!
Nice work! @drrossanarosa.bsky.social have you found a disinfectant for inpatient rooms that can be used universally regardless of colonization status or do auris rooms get their own cleaning/disinfection protocol?
August 28, 2025 at 10:37 PM
Nice work! @drrossanarosa.bsky.social have you found a disinfectant for inpatient rooms that can be used universally regardless of colonization status or do auris rooms get their own cleaning/disinfection protocol?
Welcome! Weβre thrilled to have you.
July 9, 2025 at 9:19 PM
Welcome! Weβre thrilled to have you.
Very cool thanks for sharing.
April 10, 2025 at 4:36 PM
Very cool thanks for sharing.
Let us know what you decide!
February 28, 2025 at 5:42 AM
Let us know what you decide!
π so very sorry to hear
January 12, 2025 at 12:47 AM
π so very sorry to hear
Reposted by Seth Cohen
π¨π£π¨π£
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
December 17, 2024 at 12:08 AM
π¨π£π¨π£
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
@pergamic.bsky.social @johnlynchid.bsky.social @paulpottingermd.bsky.social @germhuntermd.bsky.social @drrossanarosa.bsky.social @jlsalinas.bsky.social
Graduating fellows with interests in scholarship, med-ed, IP and clinical service are welcome to apply!
Graduating fellows with interests in scholarship, med-ed, IP and clinical service are welcome to apply!
π¨π£π¨π£
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
We're hiring!
Open search for Associate Director of Infection Prevention at UW Medical Center
Work in amazing academic environment with a phenomenal team.
Fantastic quality of life.
Did I mention protected time for scholarly activities?
DM w q's
apply.interfolio.com/160509
#IDsky
December 17, 2024 at 12:12 AM
@pergamic.bsky.social @johnlynchid.bsky.social @paulpottingermd.bsky.social @germhuntermd.bsky.social @drrossanarosa.bsky.social @jlsalinas.bsky.social
Graduating fellows with interests in scholarship, med-ed, IP and clinical service are welcome to apply!
Graduating fellows with interests in scholarship, med-ed, IP and clinical service are welcome to apply!